Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
about
Regulation of the latent-lytic switch in Epstein-Barr virusAdoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized miceRecent insights in the pathogenesis of post-transplantation lymphoproliferative disordersEpstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesisEpstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial MalignanciesReplication of Epstein-Barr virus primary infection in human tonsil tissue explants.Herpesviruses dUTPases: A New Family of Pathogen-Associated Molecular Pattern (PAMP) Proteins with Implications for Human DiseaseEpstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication.CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infectionDegradation of phosphorylated p53 by viral protein-ECS E3 ligase complex.Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disordersArsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoterEpstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1Human viruses and cancer.A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.The nuclear and adherent junction complex component protein ubinuclein negatively regulates the productive cycle of Epstein-Barr virus in epithelial cellsThe impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapyTegument protein control of latent herpesvirus establishment and animation.Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumorsγ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation.Epstein-Barr virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin-10 production from monocytesInduction of Epstein-Barr virus (EBV) lytic cycle in vitro causes lipid peroxidation, protein oxidation and DNA damage in lymphoblastoid B cell linesThe B subunit of Escherichia coli enterotoxin helps control the in vivo growth of solid tumors expressing the Epstein-Barr virus latent membrane protein 2A.Genome-wide analysis of Epstein-Barr virus Rta DNA bindingThe Epstein-Barr virus BcRF1 gene product is a TBP-like protein with an essential role in late gene expression.An Epstein-Barr Virus-Encoded Protein Complex Requires an Origin of Lytic Replication In Cis to Mediate Late Gene Transcription.An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells.Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.Epstein-Barr virus: evasive maneuvers in the development of PTLD.Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expressionEBV reactivation as a target of luteolin to repress NPC tumorigenesis.Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines.
P2860
Q27021366-DA5C78F9-3137-47F1-ABD2-AFBC5A2FB525Q27324235-60DC281F-948B-4488-BD08-7DCB01F07BD9Q28075701-34C49DC4-32C0-4B9D-BCA6-519EF9F93058Q28079510-1D21E9A3-C91F-4D50-AED8-1F69BECB13D4Q28284628-18955D89-A454-4312-ABC2-870F8E5B1974Q28551855-DB050B74-16B5-43AF-A2C9-08A9C2625702Q31037038-368521EC-C115-4998-8FAC-D20B350C0804Q31152067-61F514B6-12AB-4A91-A718-989BDF1A0D5FQ33321474-D287881C-A02A-448E-9165-791408BA23CEQ33374980-B897E83C-BCAC-4B8E-9203-DD1CCD6DAB6BQ33489621-88EA4819-A504-48D6-A9FF-E03A6FCBF810Q33650689-B08DDA60-9C08-43C8-98BC-8FA6489DBA16Q33823359-E3062D30-6590-4A99-BE15-0293C85B42BEQ33923073-F9D9CA81-14B9-4FB9-BC4E-C1E04673F050Q34123922-0DF1754C-ACAA-4A93-AB4F-9F179B1A8DCCQ34405076-16C82C6C-C975-4BEA-9F0C-1D704FEA3F94Q34423461-4219FEE1-DCA9-40AC-AA11-DB9B7A7F980CQ34457976-4BEAA597-CC7C-45FA-859B-9D7E6E2FED3FQ34485205-72F75B6D-67BB-4235-ACE4-FEB594C1E9DFQ34610984-D370A292-467F-4411-8843-EB559E3383A9Q34712750-B94DBD3C-2DE0-49D4-921C-CF571AF8CBDDQ34720273-31D5484A-FA7F-4D67-9EA3-DAF1565FC52CQ34767204-3AFA420F-666C-46D6-878E-DAC8088E0A5EQ35068371-AD3CF8E5-1B74-4A83-8321-8A78F7F9DFC9Q35077651-287171D7-0957-4BF3-BE8E-A84EB432D9EDQ35137340-B4A3AFE9-8DA1-4E03-ACA0-D40436B98C58Q35236817-9BEF469E-5EB0-41EB-9CBC-A18DCE139874Q35943838-A812517D-E6B0-41FC-9E1D-FBEC70F4FBE2Q36023187-9C58B195-8531-44C0-9732-A67759963B51Q36062461-C05B4709-28CF-476E-BBC5-CCDF5290F67AQ36171933-1C57F1A6-6C1E-4E68-B1A5-55B11E95A827Q36205880-AECEF6D8-1453-4AEB-BE23-50B72C120F49Q36498181-418E98C7-2C51-4CF7-94BF-F5EA7D3E8E67Q36537637-07E06E74-9D08-4F62-B920-A0EB4830C9F5Q36710230-577A653A-212A-46D3-91E8-5300699B6D45Q36804608-EAEF4E2B-012E-4E51-951F-FC6952F38299Q37109915-00573596-3E78-4347-A515-8605C44377E2Q37146126-E289AC54-D693-4C1C-B4D6-19B36BEA80AFQ37252690-C3AA3F04-C689-4492-8B6C-23C9925C2C2BQ37262460-84E7CCCD-6A08-4267-B8DD-77EAAF4CFC38
P2860
Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@ast
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@en
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@nl
type
label
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@ast
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@en
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@nl
prefLabel
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@ast
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@en
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@nl
P2093
P2860
P1433
P1476
Epstein-Barr virus lytic infec ...... disease in a SCID mouse model.
@en
P2093
Elizabeth Holley-Guthrie
Gregory K Hong
Margaret L Gulley
Shannon C Kenney
Wen-Hai Feng
P2860
P304
13993-14003
P356
10.1128/JVI.79.22.13993-14003.2005
P407
P577
2005-11-01T00:00:00Z